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Abstract
Background: Coronary heart disease (CHD) is the leading cause of death in the United States.
Previous research examining physicians ability to estimate cardiovascular risk has shown that
physicians' generally overestimate the absolute risk of CHD events. This question has, however,
only studied risk prediction for a limited number of patient care scenarios. The aim of this study is
to measure the ability of physicians to estimate the risk of CHD events in patients with no previous
history of coronary heart disease.
Methods: Twelve primary prevention scenarios with a 5-year risk of CHD events were developed.
This questionnaire was surveyed at 3 university teaching hospitals where the participants were a
convenience sample of internal medicine residents and fellows or attending physicians in general
internal medicine or cardiology. For each scenario, physicians were asked to estimate the baseline
5-year risk of a coronary heart disease event and the revised risk if the patient were to receive
lipid-lowering drug therapy. Estimates of the baseline 5-year risk were compared with values
calculated from Framingham risk equations. Inaccurate responses were defined as those with a
ratio of estimated to actual risk of more than 1.5 or less than 0.67. Physicians' estimates of the
relative risk reduction with therapy were considered to be accurate if they were between 25% and
40%.
Results: 79 physicians (53 residents, 8 fellows, 18 attending physicians) completed the survey. Only
24% of physicians' risk estimates were accurate. In most cases, physicians overestimated the
absolute risk of cardiovascular events without therapy (proportion overestimating ranged from 32–
92% for the 12 individual scenarios). Physicians made larger errors in patient scenarios involving
patients with high total or LDL cholesterol levels. Physicians' estimates of the relative risk reduction
from treatment were more accurate: 43% of estimates were between 25 and 40%. Over 85% of
physicians recommended treatment in 10 of 12 scenarios.
Conclusions: Physicians overestimate the absolute risk of CHD events and the potential absolute
benefit of drug therapy.
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Background
Coronary heart disease is the leading cause of death in the
United States.[1] Each year, more than 1,000,000 Ameri-
cans experience new or recurrent myocardial infarction or
fatal coronary heart disease (CHD). About one-third of
these events will be fatal, and approximately 650,000 of
these events will be a first myocardial infarction. The
direct and indirect costs of CHD and stroke are estimated
to be $130 billion for 2003.[2] Fortunately, there are a
number of interventions that can reduce the risk of CHD
events in patients with no previous history of CHD,
including smoking cessation counseling, hypertension
treatment, aspirin prophylaxis, and treatment of lipid
disorders.[3–7]
Systematic reviews and recent trials have found that lipid-
lowering therapy with HMG co-A reductase inhibitors
(statins) can reduce the relative risk of future CHD events
by approximately 30% and that this relative risk reduction
appears to be similar for patients with different levels of
CHD risk. [7]. These findings suggest that the absolute
benefit from statin therapy is proportional to the patient's
baseline level of CHD risk. Patients with a previous his-
tory of cardiovascular disease (CVD) are at high risk and
generally warrant aggressive treatment; patients with no
previous CVD history have a wide range of underlying
CHD risk and hence require individualized decisions for
optimal care. In order to make effective and efficient deci-
sions about whether a patient without prior CVD should
receive lipid-lowering drugs, providers must implicitly or
explicitly consider the patient's risk of future CHD events.
Previous research examining providers' ability to estimate
cardiovascular risk has shown that providers generally
overestimate the absolute risk of CHD events but are more
accurate in their assessment of relative risk reductions.[8–
12] If providers overestimate the absolute risk of CHD
events prior to treatment, their estimates of the absolute
benefit of therapy may also be inaccurate. Previous studies
examining this question have only studied risk prediction
for a limited number of patient care scenarios, making it
difficult to examine how specific patient characteristics or
the degree of baseline risk (low, medium, or high risk)
affect risk prediction and the amount or degree of
overestimation.
We sought to examine physicians' ability to predict the
risk of CHD events and the effect of pharmacological
lipid-lowering therapy for a wide range of primary preven-
tion scenarios by asking physicians at three academic
medical centers to complete a survey of 12 hypothetical
scenarios concerning patients with different levels of CHD
risk.
Methods
Questionnaire Development
We used the Framingham risk equations [13] to develop
12 primary prevention scenarios with 5-year risk of CHD
events (defined as new onset angina, non-fatal or fatal MI,
or sudden death) from 1 to 22 per cent. The scenarios
were balanced with regard to gender (6 male patients, 6
female patients) and included 4 low-risk scenarios (less
than 5% risk of CHD events over 5 years), 4 medium risk
scenarios (5-year risk of 5–9%), and 4 high-risk scenarios
(5-year risk 10–22%). Six of the scenarios had one or no
additional risk factors (not including age, gender, or lipid
levels), while the other 6 scenarios had 2 or more addi-
tional risk factors.
The hypothetical patients were explicitly assumed: 1) to
not be taking aspirin or lipid-lowering agents at baseline;
2) to not have responded to a trial of a low-fat diet; 3), to
not be overweight; and 4) to not have a family history of
early myocardial infarction. We did not specify the
patient's ethnicity, as we did not wish to examine its effect
in this study.
The questionnaire was pilot tested in two different groups
of primary care providers and preventive medicine resi-
dents at one of the study sites and was revised based on
their feedback.
Study Subjects and Administration
In the fall of 1998 we administered the survey to residents,
fellows, and attending physicians at three university sites.
Potential respondents were invited to a lunch meeting in
which they would complete a survey on preventive care.
They provided informed consent and then completed the
survey over the course of the next 20–30 minutes. Subjects
were not allowed to use decision aids or other external
information. The protocol was considered exempt by the
UNC Institutional Review Board.
Outcome Measures
For each scenario, we first asked subjects to estimate the 5-
year risk of CHD events without any therapy, then to esti-
mate the 5-year risk if the patient were taking a lipid-low-
ering agent. We used a 5-year time range, rather than the
10-year range used by some risk estimation tools, because
trials examining the benefits of lipid-lowering therapy
were performed over a mean of 5 years, making estimates
of treatment effectiveness over this time period most
robust. Finally, providers were asked to indicate on a 4-
point Likert scale if they would recommend that the
patient take lipid-lowering therapy, with responses rang-
ing from "strongly recommend therapy" to "strongly rec-
ommend against therapy". For these analyses, strong or
moderate recommendations for therapy were considered
as positive.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/13
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Analysis
Data from completed surveys were entered and analyzed
using STATA 6.0. (Stata Corporation, College Station, Tx)
and Microsoft Excel (Microsoft, Redmond, WA). Univari-
ate frequencies are presented as proportions, means, and
medians. We measured the accuracy of CHD risk predic-
tion by dividing the subjects' estimate of risk by the risk
obtained from the Framingham model and considering
results from 0.67 to 1.5 to be accurate. The accuracy of
physicians' estimates of CHD risk after therapy with lipid-
lowering drugs was examined by calculating the relative
risk reduction (RRR, defined as the baseline risk – risk
after therapy, divided by the baseline risk) and comparing
it against a value of 30% derived from a meta-analysis of
primary prevention trials. [7] Relative risk reductions
between 25 and 40% were considered to be accurate. To
examine patient factors that may be associated with the
accuracy of risk estimation, we compared the mean rela-
tive over-estimations for scenarios using patients with the
factor compared with scenarios of patients without the
factor, using Wilcoxon rank sum tests for univariate anal-
yses and linear regression for multivariate analysis.
We did not attempt to compare the risk prediction ability
of residents (compared with attendings) or cardiologists
(compared with generalists) because of the small num-
bers of participants in each sub-group.
Results
Seventy-nine respondents completed the survey (53 resi-
dents, 8 fellows, and 18 attending physicians). Mean age
was 31 years and 65% were men. Of the 8 fellows and 18
attending physicians, 77% were general internists and
23% were cardiologists.
Accuracy of risk estimates
Across all 12 scenarios, risk estimates were accurate (a
response between 0.67 and 1.5 times the actual value) for
only 24% of the responses. Most physicians overestimated
the 5-year risk of CHD: for all scenarios combined, 66%
of responses were overestimates, defined as 1.5 times
greater than the actual value. For the 12 individual ques-
tions, the proportion of physicians overestimating risk
ranged from 33 to 99 %. Fewer providers underestimated
risk: 10% responses were underestimates (less than 0.67
times the actual value). For the 12 individual scenarios,
the proportion of physicians underestimating risk ranged
from 0 to 29%. When an alternative definition of accuracy
(estimates within 10 percentage points of the true value),
similar patterns were noted.
Estimation of relative risk reduction
Physicians were more accurate in their ability to estimate
the relative risk reduction that would be associated with
lipid-lowering therapy: 43% of estimates were accurate.
By scenario, the range of accurate calculated RRR was 29
to 53%.
Treatment recommendations
Most physicians (over 85% in scenarios # 3–12; 32% in
scenario #1 and 67% in scenario #2) recommended treat-
ment with statin drugs. The two scenarios with lower
treatment recommendation rates were the two of the four
lowest risk scenarios.
Patient factors affecting degree of risk over-estimation
The mean degree of over-estimation, expressed in relative
terms, was larger for low-risk scenarios (mean physician
estimate 7.8 times Framingham estimate), intermediate
for medium risk scenarios (2.8 times), and smaller (1.5
times) for high-risk scenarios. Table 2 shows univariate
analyses of the median degree of overestimation for sce-
narios with and without specific patient characteristics.
Physicians were more likely to overestimate risk for
patients with very high cholesterol levels (total cholesterol
> 260 mg/dl) than for patients with more modest eleva-
tions. Scenarios in which the patient had other CHD risk
factors produced smaller over-estimations than when
those factors were absent. Multivariate linear regression
analysis revealed similar patterns of results. (data not
shown)
Discussion
In this scenario-based study, academic physicians overes-
timated the risk of CHD events across a range of patient
risk profiles encountered in primary prevention. Scenarios
with young patients, female patients, and very high lipid
levels led to the highest degrees of overestimation. Their
estimates of the relative risk reduction associated with
therapy using lipid-lowering drugs were more accurate,
but their estimates of the absolute risk reductions were
also inaccurate because of their overestimation of baseline
CHD risk. Perhaps because of the over-estimation of risk
and the potential benefits of treatment, most physicians
recommended treatment in most scenarios, even those
with relatively low risk.
Our study provides additional insight into the ways in
which providers misestimate risk. It appears that provid-
ers are more likely to overestimate risk in young adults
and women, after adjusting for other risk factors, and are
less likely to make such overestimations when other risk
factors are present. These findings suggest that providers'
heuristics may be systematically inaccurate. Whether feed-
back of these particular errors could improve risk estima-
tion has not been examined.
Although we did not study actual provider behavior, our
study suggests that efforts to improve the low utilization
of statin drugs in high-risk patients cannot rely solely onBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/13
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educational efforts aimed at increasing the awareness of
risk or the benefit of treatment. Knowledge of risk, or the
advantages of treatment, do not appear to be important
barriers in the decision to prescribe lipid lowering agents
among physicians at academic medical centers.
Our findings are consistent with previous research that
has examined physicians' ability to predict the risk of
CHD events and found that physicians misestimate abso-
lute risk. Friedmann et al used a mail survey to measure
599 physicians' estimates of risk for three CHD risk sce-
narios, one of which involved lipid-lowering therapy. [9]
They found that cardiologists were more accurate in their
perceptions of the underlying risk of CHD than general
internists and family physicians, but that estimates of rel-
ative risk reduction were generally accurate for all special-
ties. Cardiologists recommended treatment more often
than generalists, even though they perceived the benefit to
be smaller.
Grover surveyed 253 Canadian physicians about their
estimates of 8-year risk of CHD in two hypothetical sce-
narios, one involving a 40 year old male, and the second
involving a 70 year-old female patient. [8] The mean esti-
Table 1: Provider estimates of risk and proportion of inaccurate estimates
# Clinical history CHD 5-year 
risk*
Mean/Median 
provider 
estimates of 5-
year risk
% of providers 
overestimating 
risk by more 
than 1.5x
% of providers 
underestimating 
risk (ratio less 
than 0.67)
% of providers 
who 
overestimate 
risk by >= 10 
percentage 
points
% of providers 
who 
underestimate 
risk by < 10 
percentage 
points
% of providers 
recommending 
treatment with 
statin drug
1 49 yo man with TC = 240, 
LDL = 140, HDL = 50. Non-
smoker, no history of 
diabetes; BP = 114/74.
3% 6.8% / 5% 67.1% 11.4% 34.2% NA 31.6%
2 43 yo woman with TC = 278, 
LDL = 192, HDL = 48. Non-
smoker, no history of 
diabetes; BP = 136/86.
1% 7.2% / 5% 89.9% 0.0% 34.2% NA 67.1%
3 68 yo man with TC = 240, 
LDL = 150, HDL = 40. (+) 
smoker, (+) diabetes, BP = 
110 / 70
22% 26.0% / 25% 32.9% 25.3% 84.8% 15.2% 97.5%
4 42 yo man with total 
cholesterol = 260, LDL = 192, 
HDL = 30. (+) smoker 
(+)diabetes, BP = 110 / 70
10% 18.2% / 15% 46.8% 12.7% 81.0% NA 97.5%
5 42 yo woman with TC = 290, 
LDL = 200, HDL = 45. (+) 
smoker; (+) diabetes, BP = 
114/ 74
3% 15.1% / 15% 92.4% 0.0% 73.4% NA 96.2%
6 73 yo man with TC = 255, 
LDL = 165, HDL = 42. Non-
smoker; no diabetes; BP = 
150/88
18% 23.3% / 20% 27.8% 29.1% 83.5% 16.5% 89.9%
7 74 yo woman with TC = 270, 
LDL = 170, HDL = 40. Non-
smoker; no diabetes; BP = 
148/92
7% 19.6% / 15% 65.8% 5.1% 77.2% NA 84.8%
8 40 yo man with TC = 235, 
LDL = 165, HDL = 40. (+) 
smoker; no diabetes; BP = 
145/91
6% 14.6% / 10.5% 65.4% 7.7% 64.6% NA 92.4%
9 68 yo woman with TC = 244, 
LDL = 155, HDL = 37. (+) 
smoker (+)diabetes, BP = 114 
/ 74
9% 22.6% / 20% 68.4% 8.9% 81.0% 19.0% 97.5%
10 52 yo man with TC = 320, 
LDL = 210, HDL = 45. Non-
smoker, no history of 
diabetes; BP = 122/74
5% 17.9% / 15% 79.7% 0.0% 74.7% NA 97.5%
11 54 yo woman with TC = 330, 
LDL = 235, HDL = 60. Non-
smoker, no history of 
diabetes; BP = 114/74
1% 17.0% / 15% 98.7% 0.0% 68.4% NA 93.7%
12 56 yo woman with TC = 264, 
LDL = 200, HDL = 34. (+) 
smoker; no diabetes; BP = 
155/90
12% 23.5% / 20% 53.2% 3.8% 91.1% 8.9% 98.7%
Abbreviations: NA = not applicable, TC = serum total cholesterol, LDL = low density lipoprotein cholesterol, HDL = high density lipoprotein 
cholesterol, BP = blood pressure. Risk of myocardial infarction, sudden death, or new-onset angina as calculated from the Framingham risk 
equationsBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/13
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mates of risk were higher than actual risk in both scenar-
ios, but the degree of overestimation was larger for the 40
year-old male patient. They also overestimated the poten-
tial years of life saved for a series of CHD interventions.
Chatellier et al provided clinical information about 66
patients to 6 physicians and asked the physicians to esti-
mate the patients' CHD risk. Physicians had widely vary-
ing estimates of risk in comparison with Framingham-
derived estimates. The agreement between the Framing-
ham estimates and physicians' estimates were only mod-
erately better than chance for 5 of the 6 physicians. [10]
McManus examined the ability of practice nurses and gen-
eral practitioners in central England to estimate risk using
actual patients identified from computerized records. Pro-
viders' subjective assessments and risk calculations from 4
risk assessment tools were compared against Framingham
estimates. The subjective assessments were less accurate
than those estimates generated from properly completed
risk tool calculations, with relatively equal number of
overestimation and underestimation.[11]
Montgomery and colleagues evaluated the cardiovascular
risk prediction ability of 69 general practitioners and 11
practice nurses in the United Kingdom. Providers were
asked to estimate the risk of cardiovascular events for a
series of older patients (ages 60–79) with hypertension
who were being seen in the practice for a blood pressure
check. [12] Estimates were compared to the Framingham-
calculated risk. Estimates were accurate in 21% of cases;
63% were underestimates and 16% overestimates. The
large number of underestimates stands in contrast to our
study, and others [8,9] that mainly identified overestima-
tion errors. This difference may result from the generally
high risk of the patients included in the study by Mont-
gomery and colleagues (60% had a 5 year risk greater than
15%). It is less likely, although plausible, that the use of
real patients may produce systematically different results
than the use of hypothetical vignettes.
Our study, like several previous studies in this area, is lim-
ited by the use of hypothetical scenarios completed out-
side of usual practice. Actual patterns of risk estimation
and treatment recommendation may differ from these
examples. However, studies suggest that vignettes provide
accurate information about actual physician prac-
tice.[14,15] Our use of a convenience sample of physi-
cians limits the generalizability of our results. To limit the
effect of our sampling strategy on the validity of our
results, we did not inform potential subjects of the specific
nature of the study prior to their decision to participate.
Our choice of a relative measure for degree of inaccuracy
may have increased the apparent degree of inaccuracy for
low-risk scenarios. However, alternate analysis using
absolute measures found similar patterns. Our decision to
use 5 year risk, rather than the more commonly used 10
year risk, could have led to inaccurate risk estimation. We
attempted to limit this effect by reinforcing verbally and
in writing that we were asking for 5 year estimates. Finally,
we did not vary the order of the scenarios. Subjects may
have become fatigued or may have learned from answer-
ing the earlier scenarios, but we could detect no such
pattern.
Conclusion
Despite these limitations, our findings suggest that physi-
cians overestimate the risk of CHD events, particularly
when the "patient" has very high total or LDL cholesterol
levels and in low-risk scenarios, particularly those involv-
ing women, younger patients, and those without other
CHD risk factors. Providers' difficulties in estimating
CHD risk should not be surprising, since accurate estima-
tion requires integration of several different pieces of clin-
ical information, some of which are categorical (smoking
versus no smoking) and others of which are continuous
(age, blood pressure). Findings from the field of cognitive
psychology suggest that when faced with complex ques-
tions, people, including health care providers, utilize sim-
pler "rules-of-thumb" or heuristics to make decisions.[16]
In some cases these heuristics serve quite well; in other
Table 2: The effect of patient characteristics on the relative estimation medians for all responses.
Median Relative Estimation Ranksum Test
Factor Present Absent p value
Diabetes 1.8 2.3 0.0001
Hypertension 1.6 2.7 0.0000
Smoking 1.7 2.9 0.0000
Male sex 1.7 3.3 0.0000
Age >= 65 1.4 3.0 0.0000
Total cholesterol > 260 mg/dl 3.1 1.7 0.0000
HDL cholesterol <= 40 mg/dl 1.7 3.3 0.0000Publish with BioMed Central    and   every 
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cases, they may lead to common, reproducible errors in
judgment. Inaccurate estimates of CHD risk could lead to
prescription of lipid lowering drugs to patients in whom
their net benefit has not been established. [17]
Inaccurate risk estimation and over-prescription of risk-
reducing therapies can also have economic consequences.
Cost-effectiveness analyses suggest that the cost per life-
year saved and total costs rise dramatically as treatment is
extended to lower-risk patients. [18] Accurate risk assess-
ment is crucial for making rationale treatment decisions.
Fortunately, several easy to use and accurate CHD risk pre-
diction tools are now available. [19] They can improve the
accuracy of risk predictions [11] are becoming more
widely disseminated, and may improve the quality of
treatment decisions, although further research on their
effect is required.
Competing interests
After the completion of this research, Dr. Michael Pignone
has received licensing and consulting fees from Bayer, Inc.
for the development of a CHD risk estimation tool.
Authors' Contributions
Michael Pignone conceived of the idea for the study. He
supervised study design, recruited co-investigators, over-
saw pilot testing and data collection at one site, and par-
ticipated in data analysis. He drafted and revised the
manuscript. Chris Phillips participated in study design,
conducted data analysis, and created tables. He also par-
ticipated in manuscript editing. Tom Elasy and Alicia
Fernandez acted as site supervisors for data collection and
revised the manuscript.
Acknowledgements
The authors thank Gaily Szeto for her administrative assistance in prepar-
ing, submitting, and revising the manuscript. Funding Source – Robert 
Wood Johnson Clinical Scholars Program
References
1. Hoyert DL, Kochanek KD and Murphy SL: Deaths: final data for
1997 Natl Vital Stat Rep 1999, 47:1-104.
2. American Heart Association: 2002 Heart and Stroke Statistical
Update. 30 .
3. The health benefits of smoking cessation: a report of the
Surgeon General Rockville, US Department of Health and Human
Services, Public Health Service, and Centers for Disease Control .
4. Pignone M and Mulrow CD: Evidence based management of
hypertension: Using cardiovascular risk profiles to individu-
alise hypertensive treatment BMJ 2001, 322:1164-6.
5. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD and Lohr
KN: Screening and treating adults for lipid disorders Am J Prev
Med 2001, 20:77-89.
6. Hayden M, Pignone M, Phillips C and Mulrow C: Aspirin for the pri-
mary prevention of cardiovascular events: a summary of the
evidence for the u.s. Preventive services task force Ann Intern
Med 2002, 136:161-72.
7. Pignone M, Phillips C and Mulrow C: Use of lipid lowering drugs
for primary prevention of coronary heart disease: meta-
analysis of randomised trials BMJ 2000, 321:983-6.
8. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L and Abra-
hamowicz M: Do doctors accurately assess coronary risk in
their patients? Preliminary results of the coronary health
assessment study BMJ 1995, 310:975-8.
9. Friedmann PD, Brett AS and Mayo-Smith MF: Differences in gener-
alists' and cardiologists' perceptions of cardiovascular risk
and the outcomes of preventive therapy in cardiovascular
disease Ann Intern Med 1996, 124:414-21.
10. Chatellier G, Blinowska A, Menard J and Degoulet P: Do physicians
estimate reliably the cardiovascular risk of hypertensive
patients? Medinfo 1995, 8 Pt 2:876-9.
11. McManus RJ, Mant J, Meulendijks CF, Salter RA, Pattison HM and
Roalfe AK et al.: Comparison of estimates and calculations of
risk of coronary heart disease by doctors and nurses using
different calculation tools in general practice: cross sectional
study BMJ 2002, 324:459-64.
12. Montgomery AA, Fahey T, MacKintosh C, Sharp DJ and Peters TJ:
Estimation of cardiovascular risk in hypertensive patients in
primary care Br J Gen Pract 2000, 50:127-8.
13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H and
Kannel WB: Prediction of coronary heart disease using risk
factor categories Circulation 1998, 97:1837-47.
14. Peabody JW, Luck J, Glassman P, Dresselhaus TR and Lee M: Com-
parison of vignettes, standardized patients, and chart
abstraction: a prospective validation study of 3 methods for
measuring quality JAMA 2000, 283:1715-22.
15. Dresselhaus TR, Peabody JW, Lee M, Wang MM and Luck : Measur-
ing compliance with preventive care guidelines: standard-
ized patients, clinical vignettes, and the medical record J Gen
Intern Med 2000, 15:782-8.
16. Redelmeier DA, Ferris LE, Tu JV, Hux JE and Schull MJ: Problems for
clinical judgement: introducing cognitive psychology as one
more basic science CMAJ 2001, 164:358-60.
17. Jackson PR, Wallis EJ, Haq IU and Ramsay LE: Statins for primary
prevention: at what coronary risk is safety assured? Br J Clin
Pharmacol 2001, 52:439-46.
18. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU and Yeo WW et
al.: Cost effectiveness of HMG-CoA reductase inhibitor (sta-
tin) treatment related to the risk of coronary heart disease
and cost of drug treatment Heart 1999, 82:325-32.
19. Grundy SM: Primary prevention of coronary heart disease:
integrating risk assessment with intervention Circulation 1999,
100:988-98.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/3/13/prepub